| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Infections | 36 | 2021 | 11620 | 1.88 | Why? |
| Infectious Disease Medicine | 3 | 2021 | 311 | 1.38 | Why? |
| Homosexuality, Male | 11 | 2020 | 1158 | 1.03 | Why? |
| Transition to Adult Care | 2 | 2018 | 56 | 0.87 | Why? |
| Social Capital | 2 | 2019 | 159 | 0.75 | Why? |
| Schools, Public Health | 1 | 2017 | 10 | 0.71 | Why? |
| Consumer Advocacy | 1 | 2018 | 62 | 0.69 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.69 | Why? |
| Anti-Retroviral Agents | 4 | 2020 | 1099 | 0.67 | Why? |
| Preceptorship | 1 | 2017 | 115 | 0.62 | Why? |
| Case Management | 1 | 2018 | 285 | 0.59 | Why? |
| Sexual and Gender Minorities | 6 | 2020 | 1019 | 0.56 | Why? |
| Georgia | 10 | 2020 | 955 | 0.54 | Why? |
| Pre-Exposure Prophylaxis | 6 | 2020 | 1138 | 0.43 | Why? |
| Patient Transfer | 1 | 2018 | 898 | 0.43 | Why? |
| Epidemics | 4 | 2021 | 6407 | 0.43 | Why? |
| HIV | 5 | 2021 | 1116 | 0.42 | Why? |
| Veterans | 1 | 2021 | 1131 | 0.42 | Why? |
| Education, Medical, Continuing | 1 | 2017 | 638 | 0.42 | Why? |
| Temperature | 1 | 2020 | 2305 | 0.41 | Why? |
| Southeastern United States | 2 | 2020 | 141 | 0.39 | Why? |
| Patient-Centered Care | 1 | 2018 | 860 | 0.39 | Why? |
| Symptom Assessment | 2 | 2021 | 4967 | 0.39 | Why? |
| Anti-HIV Agents | 6 | 2020 | 2209 | 0.39 | Why? |
| Prisoners | 1 | 2018 | 738 | 0.38 | Why? |
| Communicable Diseases | 3 | 2019 | 2148 | 0.38 | Why? |
| Learning | 1 | 2017 | 1181 | 0.37 | Why? |
| Immunization Programs | 1 | 2021 | 2006 | 0.37 | Why? |
| Bisexuality | 2 | 2019 | 119 | 0.36 | Why? |
| Prisons | 1 | 2018 | 980 | 0.36 | Why? |
| Urban Population | 2 | 2018 | 2000 | 0.34 | Why? |
| Africa, Eastern | 2 | 2017 | 90 | 0.34 | Why? |
| Public Health | 8 | 2021 | 16359 | 0.34 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.32 | Why? |
| Drug Users | 3 | 2018 | 234 | 0.32 | Why? |
| Pneumonia, Viral | 16 | 2020 | 243684 | 0.32 | Why? |
| Chronic Pain | 3 | 2019 | 736 | 0.32 | Why? |
| Coronavirus Infections | 16 | 2020 | 253789 | 0.31 | Why? |
| Opioid-Related Disorders | 1 | 2018 | 1185 | 0.31 | Why? |
| Healthcare Disparities | 2 | 2021 | 3893 | 0.30 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.30 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.30 | Why? |
| Viral Load | 8 | 2020 | 15850 | 0.30 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.29 | Why? |
| African Americans | 7 | 2020 | 3363 | 0.29 | Why? |
| Neisseria meningitidis | 2 | 2017 | 229 | 0.29 | Why? |
| Global Health | 6 | 2021 | 13911 | 0.29 | Why? |
| Analgesics, Opioid | 3 | 2019 | 1070 | 0.29 | Why? |
| Clinical Laboratory Techniques | 7 | 2020 | 23402 | 0.29 | Why? |
| United States | 20 | 2021 | 46150 | 0.28 | Why? |
| Betacoronavirus | 14 | 2020 | 204454 | 0.28 | Why? |
| Humans | 77 | 2021 | 930598 | 0.28 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.28 | Why? |
| Drug Resistance, Viral | 3 | 2020 | 1083 | 0.26 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.25 | Why? |
| History, 20th Century | 2 | 2020 | 1282 | 0.24 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.24 | Why? |
| Pandemics | 17 | 2021 | 389249 | 0.23 | Why? |
| HIV-1 | 4 | 2020 | 3365 | 0.23 | Why? |
| Domestic Violence | 2 | 2018 | 522 | 0.22 | Why? |
| Acquired Immunodeficiency Syndrome | 3 | 2019 | 533 | 0.21 | Why? |
| Substance-Related Disorders | 4 | 2019 | 2038 | 0.21 | Why? |
| Time-to-Treatment | 2 | 2018 | 5883 | 0.21 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.21 | Why? |
| HIV Seronegativity | 2 | 2017 | 112 | 0.20 | Why? |
| Personal Space | 1 | 2020 | 96 | 0.20 | Why? |
| Societies | 1 | 2019 | 95 | 0.19 | Why? |
| Recidivism | 1 | 2018 | 9 | 0.19 | Why? |
| Death Certificates | 1 | 2020 | 130 | 0.19 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.19 | Why? |
| Censorship, Research | 1 | 2018 | 8 | 0.18 | Why? |
| Marijuana Use | 1 | 2019 | 89 | 0.18 | Why? |
| HIV Integrase Inhibitors | 1 | 2020 | 173 | 0.18 | Why? |
| Seasons | 2 | 2021 | 4071 | 0.18 | Why? |
| Urethritis | 1 | 2017 | 17 | 0.18 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.18 | Why? |
| Patient Navigation | 1 | 2018 | 62 | 0.18 | Why? |
| Patient Dropouts | 1 | 2018 | 96 | 0.17 | Why? |
| Reimbursement, Incentive | 1 | 2018 | 70 | 0.17 | Why? |
| Spouse Abuse | 1 | 2018 | 55 | 0.17 | Why? |
| Students, Public Health | 1 | 2017 | 37 | 0.17 | Why? |
| HIV Integrase | 1 | 2017 | 67 | 0.17 | Why? |
| Sexism | 1 | 2021 | 278 | 0.16 | Why? |
| Cultural Diversity | 1 | 2019 | 220 | 0.16 | Why? |
| Patient Identification Systems | 1 | 2017 | 88 | 0.16 | Why? |
| Continuity of Patient Care | 2 | 2017 | 1574 | 0.16 | Why? |
| Substance Withdrawal Syndrome | 1 | 2018 | 137 | 0.16 | Why? |
| Education, Distance | 1 | 2017 | 4956 | 0.16 | Why? |
| Adult | 31 | 2021 | 244371 | 0.15 | Why? |
| Condoms | 1 | 2017 | 235 | 0.15 | Why? |
| Neisseria gonorrhoeae | 1 | 2017 | 142 | 0.15 | Why? |
| Qualitative Research | 5 | 2019 | 4337 | 0.15 | Why? |
| Meningitis, Meningococcal | 1 | 2017 | 114 | 0.15 | Why? |
| Ambulatory Care Facilities | 2 | 2017 | 2063 | 0.15 | Why? |
| Vulnerable Populations | 2 | 2020 | 3099 | 0.15 | Why? |
| Syndrome | 1 | 2020 | 1310 | 0.15 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.15 | Why? |
| Prejudice | 1 | 2018 | 245 | 0.15 | Why? |
| Analgesics | 1 | 2019 | 451 | 0.14 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.14 | Why? |
| Community Mental Health Services | 1 | 2018 | 217 | 0.14 | Why? |
| Oropharynx | 2 | 2020 | 1581 | 0.14 | Why? |
| Depression | 2 | 2018 | 14116 | 0.14 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.14 | Why? |
| Focus Groups | 1 | 2018 | 811 | 0.14 | Why? |
| Meningococcal Infections | 1 | 2017 | 216 | 0.13 | Why? |
| History, 21st Century | 2 | 2021 | 1849 | 0.13 | Why? |
| Inservice Training | 1 | 2018 | 477 | 0.13 | Why? |
| Patient Acceptance of Health Care | 3 | 2017 | 5002 | 0.13 | Why? |
| Interpersonal Relations | 2 | 2019 | 926 | 0.13 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.13 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
| Male | 34 | 2021 | 367725 | 0.13 | Why? |
| Minority Groups | 2 | 2021 | 1631 | 0.13 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.12 | Why? |
| Health Planning | 1 | 2020 | 607 | 0.12 | Why? |
| Sexual Behavior | 2 | 2019 | 1322 | 0.12 | Why? |
| Pyrrolidinones | 1 | 2012 | 66 | 0.12 | Why? |
| Vaccination Refusal | 1 | 2021 | 831 | 0.12 | Why? |
| Drug Prescriptions | 2 | 2019 | 1062 | 0.12 | Why? |
| Specimen Handling | 2 | 2020 | 6190 | 0.12 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.12 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.12 | Why? |
| Self Care | 1 | 2020 | 918 | 0.11 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.11 | Why? |
| Capacity Building | 1 | 2017 | 683 | 0.11 | Why? |
| Congresses as Topic | 1 | 2021 | 1347 | 0.11 | Why? |
| Mutation, Missense | 1 | 2017 | 863 | 0.11 | Why? |
| Adolescent | 11 | 2020 | 86841 | 0.11 | Why? |
| Medication Adherence | 2 | 2018 | 1270 | 0.11 | Why? |
| Alcoholism | 1 | 2018 | 691 | 0.11 | Why? |
| Physical Therapy Modalities | 1 | 2019 | 1090 | 0.11 | Why? |
| Hospitals, Public | 1 | 2017 | 774 | 0.10 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Faculty, Medical | 1 | 2017 | 595 | 0.10 | Why? |
| Pain Management | 1 | 2019 | 854 | 0.10 | Why? |
| Social Behavior | 1 | 2019 | 882 | 0.10 | Why? |
| Precision Medicine | 1 | 2020 | 1477 | 0.10 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.10 | Why? |
| Uncertainty | 1 | 2021 | 1888 | 0.10 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.10 | Why? |
| Fatigue | 1 | 2020 | 2479 | 0.10 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.10 | Why? |
| Cooperative Behavior | 1 | 2017 | 1216 | 0.10 | Why? |
| Social Stigma | 1 | 2018 | 1049 | 0.10 | Why? |
| Schools, Medical | 1 | 2017 | 793 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.10 | Why? |
| Interviews as Topic | 4 | 2019 | 1952 | 0.09 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.09 | Why? |
| Biomedical Research | 3 | 2018 | 5270 | 0.09 | Why? |
| Physician-Patient Relations | 1 | 2019 | 1266 | 0.09 | Why? |
| HIV Protease Inhibitors | 1 | 2012 | 434 | 0.09 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.09 | Why? |
| Teaching | 1 | 2017 | 1208 | 0.09 | Why? |
| Africa | 1 | 2017 | 2986 | 0.09 | Why? |
| Attitude to Health | 1 | 2021 | 2002 | 0.09 | Why? |
| Female | 22 | 2021 | 380317 | 0.08 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.08 | Why? |
| Physicians | 4 | 2019 | 4214 | 0.08 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.08 | Why? |
| Saliva | 2 | 2020 | 4679 | 0.08 | Why? |
| Resilience, Psychological | 2 | 2019 | 2329 | 0.08 | Why? |
| Politics | 1 | 2020 | 1824 | 0.08 | Why? |
| New York City | 1 | 2020 | 7432 | 0.08 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.08 | Why? |
| Young Adult | 9 | 2020 | 93724 | 0.08 | Why? |
| Leadership | 1 | 2020 | 2241 | 0.08 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Cough | 1 | 2020 | 4891 | 0.08 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.08 | Why? |
| Risk Factors | 7 | 2020 | 71621 | 0.08 | Why? |
| Whole Genome Sequencing | 1 | 2017 | 3239 | 0.08 | Why? |
| Health Services Accessibility | 3 | 2021 | 10697 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 2984 | 0.07 | Why? |
| Health Behavior | 2 | 2021 | 4449 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Information Dissemination | 1 | 2021 | 2986 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.07 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.06 | Why? |
| Cities | 3 | 2021 | 4937 | 0.06 | Why? |
| Fever | 1 | 2020 | 7795 | 0.06 | Why? |
| China | 2 | 2020 | 50654 | 0.06 | Why? |
| Mental Health Services | 1 | 2020 | 3007 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Cluster Analysis | 1 | 2011 | 3001 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Universities | 1 | 2017 | 4374 | 0.06 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.06 | Why? |
| Sexual Partners | 2 | 2017 | 612 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.06 | Why? |
| Pediatrics | 1 | 2017 | 2969 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.06 | Why? |
| Behavioral Sciences | 1 | 2021 | 78 | 0.05 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2020 | 2324 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.05 | Why? |
| Fees, Pharmaceutical | 1 | 2018 | 17 | 0.05 | Why? |
| International Agencies | 1 | 2020 | 202 | 0.05 | Why? |
| Internet | 1 | 2017 | 6204 | 0.05 | Why? |
| Emtricitabine | 1 | 2020 | 202 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Jealousy | 1 | 2018 | 15 | 0.05 | Why? |
| Registries | 1 | 2019 | 12327 | 0.05 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.05 | Why? |
| Cohort Studies | 5 | 2020 | 36005 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Child | 2 | 2018 | 70012 | 0.04 | Why? |
| Physician Assistants | 1 | 2019 | 115 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2020 | 260 | 0.04 | Why? |
| Marriage | 1 | 2018 | 83 | 0.04 | Why? |
| Georgia (Republic) | 1 | 2017 | 43 | 0.04 | Why? |
| Polypharmacy | 1 | 2020 | 347 | 0.04 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Capital Financing | 1 | 2017 | 35 | 0.04 | Why? |
| Lopinavir | 1 | 2012 | 4308 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Students, Medical | 1 | 2017 | 4032 | 0.04 | Why? |
| Mental Disorders | 1 | 2020 | 6742 | 0.04 | Why? |
| Drug Substitution | 1 | 2020 | 385 | 0.04 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.04 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.04 | Why? |
| Law Enforcement | 1 | 2018 | 113 | 0.04 | Why? |
| Ritonavir | 1 | 2012 | 4212 | 0.04 | Why? |
| Drug Costs | 1 | 2020 | 313 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Dried Blood Spot Testing | 1 | 2020 | 383 | 0.04 | Why? |
| Logistic Models | 3 | 2018 | 9089 | 0.04 | Why? |
| Clone Cells | 1 | 2017 | 312 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Tenofovir | 1 | 2020 | 449 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Internship and Residency | 1 | 2017 | 4987 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Treatment Refusal | 1 | 2018 | 211 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Unsafe Sex | 1 | 2016 | 139 | 0.04 | Why? |
| Boston | 1 | 2019 | 929 | 0.04 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.04 | Why? |
| National Institutes of Health (U.S.) | 1 | 2018 | 443 | 0.04 | Why? |
| Pilot Projects | 2 | 2020 | 5182 | 0.04 | Why? |
| Ohio | 1 | 2017 | 639 | 0.03 | Why? |
| Infection Control | 2 | 2021 | 23131 | 0.03 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.03 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.03 | Why? |
| Nasal Cavity | 1 | 2020 | 909 | 0.03 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.03 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.03 | Why? |
| Macrolides | 1 | 2017 | 369 | 0.03 | Why? |
| Health Services Research | 1 | 2020 | 756 | 0.03 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.03 | Why? |
| Gonorrhea | 1 | 2017 | 315 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.03 | Why? |
| Poverty | 2 | 2018 | 2302 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2019 | 9893 | 0.03 | Why? |
| Publications | 1 | 2018 | 463 | 0.03 | Why? |
| Ethiopia | 1 | 2017 | 1222 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.03 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Mental Health | 1 | 2018 | 15770 | 0.03 | Why? |
| Raltegravir Potassium | 1 | 2012 | 132 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Advisory Committees | 1 | 2018 | 1418 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Trust | 1 | 2021 | 1487 | 0.03 | Why? |
| India | 2 | 2018 | 11875 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.02 | Why? |
| CD4 Lymphocyte Count | 1 | 2012 | 1517 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Guideline Adherence | 1 | 2019 | 2309 | 0.02 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 8811 | 0.02 | Why? |
| Lipids | 1 | 2012 | 1079 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Geography | 1 | 2011 | 1801 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Nurses | 1 | 2019 | 2285 | 0.02 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.02 | Why? |
| Communication | 1 | 2021 | 5206 | 0.02 | Why? |
| Curriculum | 1 | 2017 | 3083 | 0.02 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.02 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.01 | Why? |
| Primary Health Care | 1 | 2019 | 4839 | 0.01 | Why? |
| Health Status Disparities | 1 | 2018 | 4072 | 0.01 | Why? |
| Adaptation, Psychological | 1 | 2019 | 4996 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |